SAREPTA THERAPEUTICS, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
SAREPTA THERAPEUTICS, INC. (SRPT) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $93.66 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Notes › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-03-02
- SAREPTA THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2014-09-30 was $21.98, a 43.89% decline year-over-year.
- SAREPTA THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2014-06-30 was $33.75, a 3.43% decline year-over-year.
- SAREPTA THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2014-03-31 was $26.83, a 6.71% decline year-over-year.
- SAREPTA THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2013-09-30 was $39.17.
- SAREPTA THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $93.66, a 27.33% decline from fiscal 2024.
- SAREPTA THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $128.89, a 12.74% decline from fiscal 2023.
- SAREPTA THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $147.71, a 74.39% increase from fiscal 2022.
- SAREPTA THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $84.70, a 1.98% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2025-12-31 | $93.66 10-K · filed 2026-03-02 | |||
| 2024-12-31 | $128.89 10-K · filed 2025-02-28 | |||
| 2023-12-31 | $147.71 10-K · filed 2024-02-28 | |||
| 2022-12-31 | $84.70 10-K · filed 2023-02-28 | |||
| 2021-12-31 | $86.41 10-K · filed 2022-03-01 | |||
| 2020-12-31 | $122.25 10-K · filed 2021-03-01 | |||
| 2019-12-31 | $132.97 10-K · filed 2021-03-01 | |||
| 2018-12-31 | $90.15 10-K · filed 2021-03-01 | |||
| 2017-12-31 | $35.09 10-K · filed 2020-02-26 | |||
| 2016-12-31 | $14.89 10-K · filed 2019-02-28 | |||
| 2015-12-31 | $20.28 10-K · filed 2018-03-01 | |||
| 2014-12-31 | $25.67 10-K · filed 2017-02-28 | |||
| 2014-09-30 | $21.98 10-Q · filed 2014-11-06 | $26.61 10-Q · filed 2014-11-06 | ||
| 2014-06-30 | $33.75 10-Q · filed 2014-08-07 | $27.45 10-Q · filed 2014-08-07 | ||
| 2014-03-31 | $26.83 10-Q · filed 2014-05-08 | |||
| 2013-12-31 | $34.18 10-K · filed 2016-02-25 | |||
| 2013-09-30 | $39.17 10-Q · filed 2014-11-06 | $34.86 10-Q · filed 2014-11-06 | ||
| 2013-06-30 | $34.95 10-Q · filed 2014-08-07 | $34.10 10-Q · filed 2014-08-07 | ||
| 2013-03-31 | $28.76 10-Q · filed 2014-05-08 | |||
| 2012-12-31 | $12.92 10-K · filed 2015-02-26 | |||
| 2012-09-30 | $9.19 10-Q · filed 2012-11-07 | |||
| 2012-06-30 | $6.95 10-Q · filed 2012-08-07 | |||
| 2011-12-31 | $9.18 10-K · filed 2014-03-03 | |||
| 2010-12-31 | $9.48 10-K · filed 2013-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |